Alnylam Pharmaceuticals (ALNY) Profit After Tax (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Profit After Tax came in at $164.5 million in Q2 2026, up 327.74% YoY from $38.5 million in Q2 2025, and down 20.15% on a QoQ basis from $206.0 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Profit After Tax (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Profit After Tax data on file, last reported at $164.5 million in Q2 2026.
- Quarterly Profit After Tax rose 327.74% year-over-year to $164.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $743.0 million (up 351.42% YoY) and the FY2025 annual result came in at $328.2 million, up 213.44% from the prior year.
- Profit After Tax declined to $164.5 million in Q2 2026, from $206.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $259.3 million in Q3 2025 to a low of -$407.5 million in Q3 2022.
- A 5-year average of -$66.9 million and a median of -$82.8 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2025 — Profit After Tax sank 327.66% — and 2026, when it soared 1228.66%.
- Tracing ALNY's Profit After Tax over 5 years: stood at -$208.4 million in 2022, then surged by 33.83% to -$137.9 million in 2023, then soared by 32.22% to -$93.5 million in 2024, then soared by 221.15% to $113.2 million in 2025, then surged by 45.29% to $164.5 million in 2026.
- The last three Profit After Tax figures came in at $164.5 million (Q2 2026), $206.0 million (Q1 2026), and $113.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 164.49 Mn |
| Mar 31, 2026 | 205.99 Mn |
| Dec 31, 2025 | 125.96 Mn |
| Sep 30, 2025 | 259.26 Mn |
| Jun 30, 2025 | -66.28 Mn |
| Mar 31, 2025 | -3.00 Mn |
| Dec 31, 2024 | 183.25 Mn |
| Sep 30, 2024 | 9.81 Mn |
| Jun 30, 2024 | -7.65 Mn |
| Mar 31, 2024 | -65.94 Mn |
| Dec 31, 2023 | -128.91 Mn |
| Sep 30, 2023 | 152.49 Mn |
| Jun 30, 2023 | -276.02 Mn |
| Mar 31, 2023 | -174.10 Mn |
| Dec 31, 2022 | -208.36 Mn |
| Sep 30, 2022 | -407.48 Mn |
| Jun 30, 2022 | -277.40 Mn |
| Mar 31, 2022 | -240.34 Mn |
| Dec 31, 2021 | -258.46 Mn |
| Sep 30, 2021 | -204.51 Mn |